Belite Bio Reports Third Quarter 2023 Operational
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11...
Source: globenewswire.com
Page 2 - John Grigg News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from John Grigg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In John Grigg Today - Breaking & Trending Today
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
25.04.2023 - Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time pointA continued trend of slowing expansion of autofluorescence was observedThe growth rate of incident atrophic ... Seite 1
Source: wallstreet-online.de
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
Tinlarebant continues to be safe and well tolerated in adolescent Stargardt Disease subjects at the 18-month time pointA continued trend of slowing expansion of autofluorescence was observedThe... | April 25, 2023
Source: marketscreener.com
Burns Middle mentor program makes an impact
A new mentoring program at Burns Middle pairs a Cleveland Community College athlete with a middle school student for help with homework, tutoring or just a positive outside influence.
Source: shelbystar.com
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022 - Belite Bio (NASDAQ:BLTE) - Press Release
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time pointThe majority of the subje
Source: wiredprnews.com